Femara
Company: Novartis
Approval Status: Approved July 1997
Treatment for: breast cancer
Areas: Endocrinology; Obstetrics/Gynecology; Oncology
Possible similar drugs: Femara
| General Information | Clinical Results | Side Effects | Mechanism of Action |
General Information
Femara (letrozole), a late-term hormonal therapy, has been approved as a treatment for breast cancer. Femara comes in 2.5 mg doses, recommended once daily.
Clinical Results
In a randomized study, 18.4% of patients reported a complete or partial tumor response.
Side Effects
Common side effects reported include musculoskeletal pain (21%), nausea (13%), headache (9%), joint pain (8%), or fatigue (8%).
Mechanism of Action
A second-line anti-estrogen therapy, the drug prevents the transformation of androgen compounds into estrogen by blocking the effects of the aromatase enzyme.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
